£50m Pharmacy Levy to Support Expansion of NHS Clinical Trials
Nearly £50 million from a pharmacy manufacturers’ levy will be used to expand NHS clinical trial capacity, aiming to strengthen medical research and patient access to innovative treatments.
Akanksha jain 
Nearly £50 million collected through a pharmacy manufacturers’ levy will be used to expand clinical trial capacity within the UK, according to a report.
The funding is expected to support improvements in clinical research infrastructure, enabling the NHS to conduct more trials and accelerate the development of new medicines and treatments.
Boosting Clinical Trial Capacity:
The investment will help strengthen the NHS’s ability to run large‑scale clinical studies, including those focused on innovative therapies and emerging healthcare challenges. Expanding trial capacity could also allow more patients to participate in research programs.
Clinical trials are a critical step in evaluating the safety and effectiveness of new medicines before they are approved for widespread use.
Supporting Medical Innovation
Health experts say additional funding for research infrastructure can improve the speed and efficiency of clinical trials, helping the healthcare system adopt new treatments more quickly.
By increasing research capacity, the initiative may also enhance collaboration between healthcare providers, academic researchers, and pharmaceutical companies.
Benefits for Patients and Researchers:
Expanding clinical trial opportunities within the NHS could provide patients with earlier access to innovative therapies while contributing to the global development of new medicines.
Researchers note that sustained investment in clinical research is essential for maintaining the UK’s position as a leader in medical innovation and life sciences.
